Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients with R/R large B cell lymphoma

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 1525

Prof Max Topp - University of Würzburg, Würzburg, Germany

Prof Max Topp talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of earlier steroids to improve the safety and efficacy axicabtagene ciloleucel (axi-cel) for patients with relapsed/refractory B cell lymphoma.

He reports the interim analysis of the 20 patients treated with this type of therapy and reports early use of steroids in patients with grade 1 cytokine release syndrome, none had reported any serious neurotoxicities.

As these are preliminary results, Prof Topp states that further analysis will be conducted on the remaining 40 patients that were recruited, to identify if these encouraging results are maintained.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation